Hosted on MSN17h
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...
Business Wire1d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
GlobalData on MSN1mon
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Lenacapavir/islatravir combo carries mechanistic rationale Mixed oral/subQ regimens don’t provide additional convenience ...
pharmaphorum21d
Merck halts more trials of HIV candidate islatravir
Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the highly-touted therapy. The two studies – IMPOWER 22 ...
pharmaphorum6d
Gilead and MSD say weekly oral therapy controls HIV
One patient on islatravir/lenacapavir did show a detectable viral load of more than 50 copies/mL at 24 weeks, but fell below that threshold at 30 weeks, according to Gilead and MSD, and two ...
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...
Future Market Insights11d
Injectable Drug Market Projected to Reach USD 991.63 Billion by 2034 at a 5.8% of CAGR
Injectable Drug Market. The global injectable drug market is poised for significant growth, with an estimated valuation of ...
Reuters22h
United States
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...
Le Lézard10d
momencio unveils bold new brand and industry-leading features for event success
19 oct 2024 Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in ...
Business Wire11d
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek ...